News Flash: Merck confirm anti-PD-1 melanoma phase II drug trial

Get Expert Advice

Not sure about your condition? Get in touch now, there is no reason for you to wait.

Call US: 020 3322 7852
Request a Callback

Anti-PD-1 Melanoma Phase II Drug Trial

Report from Chicago today.  The drug company Merck, confirm that the anti-PD-1 melanoma phase II drug trial is complete and the data are very impressive.  Monotherapy with the drug has shown a major survival benefit in advanced melanoma.

The drug, previously discussed in this blog, is essentially a booster to the patients own immune system which prevents the melanoma cells from avoiding detection by immune cells

Phase III clinical trials will be commenced later this year.  If you or someone you know, suffers from advanced melanoma, contact your dermatologist or oncologist for further information.

Related Posts

Melanoma Awareness Month

May is Melanoma Awareness Month

Every year, May marks an important moment for the world’s collective fight against melanoma, the deadliest form of skin cancer. It’s a time when the

Your Health Is Important

Get in touch with an expert today!
Call US: 020 3322 7852

Start Your Journey With Us

Please fill in this form and one of our team will give you a call back to arrange a consultation with one of our expert dermatologists.

Best time to call?
Please tick if you are an existing patient
This field is for validation purposes and should be left unchanged.
Call US: 020 3322 7852